FDA Approves Tremfya for Active Crohn Disease in Adults
By Lori Solomon HealthDay Reporter
MONDAY, March 24, 2025 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease.
This approval is the fourth indication for this dual-acting interleukin-23 inhibitor in the United States, making Tremfya the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for adults with Crohn disease.
The approval is based on data from three phase 3 trials. In the GRAVITI study, Tremfya (400 mg subcutaneous induction at weeks 0, 4, and 8) led to significantly higher clinical remission (56 versus 22 percent) and endoscopic response (34 versus 15 percent) when compared with placebo. Similar results were seen in the GALAXI 2 and GALAXI 3 trials, which compared Tremfya 200 mg intravenous induction at weeks 0, 4, and 8 with placebo.
"Despite the progress in the management of Crohn's disease, many patients experience debilitating symptoms and are in need of new treatment options," lead investigator of the GRAVITI study, Remo Panaccione, M.D., from the University of Calgary in Alberta, Canada, said in a statement. "Importantly, the fully subcutaneous regimen offers choice and flexibility for patients and providers that have not been available before."
Approval of Tremfya was granted to Johnson & Johnson.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Fruits And Veggies Protective Against IBD, Study Says
WEDNESDAY, July 9, 2025 — A healthy plant-based diet might protect people from inflammatory bowel diseases, a new study says. People noshing healthy plant-based foods had a...
Common Meds Aren't Linked To Inflammatory Bowel Disease, Study Says
TUESDAY, July 8, 2025 — There’s no evidence that common medications can trigger a chronic inflammatory bowel disease called microscopic colitis, a new study...
Inflammatory Bowel Disease Info Lacking On TikTok
WEDNESDAY, June 11, 2025 — Many folks with inflammatory bowel disease (IBD) are turning to TikTok for advice, but they aren’t likely to receive useful and accurate...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.